Loading...

FBRX FORTE BIOSCIENCES INC US FDA Inspections 8-K Filing

FRT

FBRX

FORTE BIOSCIENCES INC

(FBRX)

2025 8-K

Quarterly Financial Results

Financial Results Update

Equity Offerings

Clinical Trials

Financial Statements

Annual Meeting Notice

Financial Results

Equity Incentive Plan

R&D Day Announcement

Securities Placement

Financial Results

Stock Split Approved

Financial Results

Agreement and Settlement

Financial Results and Corpo...

Financial Results and Corpo...

Disclosure of Advisory Vote...

Appointment of KPMG

Equity Incentive Plan Amend...

Delisting Notice

Accountant Change

Private Placement

Rights Agreement and Extens...

Financial Results

Amendment of Bylaws

Appointment of Director

External Links:

On June 23, 2025, Forte Biosciences, Inc. announced positive results from a Phase 1b trial for its FB102 program targeting celiac disease and scheduled a conference call to discuss the findings.

AI Assistant

FORTE BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.